Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Mar 25, 2008

AstraZeneca : Phase III Studies Of The Investigational Drug Vandetanib (ZACTIMA®) In Non-Small Cell Lung Cancer (NSCLC)

March 12, 2008 AstraZeneca (NYSE: AZN) announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company’s investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies – ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) – are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008... AstraZeneca's Press Release -